达格列净治疗2型糖尿病患者非酒精性脂肪性肝病的疗效：一项荟萃分析。
Efficacy of dapagliflozin to treat nonalcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis.
作者信息
Duan Hua, Chen Fangyuan
机构信息
Department of Tuberculosis, Chengdu Public Health Clinical Medical Center, Chengdu, Sichuan, China.
Department of Internal Medicine, Nan'an District People's Hospital, Chongqing, China.
出版信息
Medicine (Baltimore). 2025 Jan 3;104(1):e40836. doi: 10.1097/MD.0000000000040836.
INTRODUCTION
Dapagliflozin shows some potential in treating nonalcoholic fatty liver disease complicated with type 2 diabetes, and this meta-analysis aims to explore the efficacy of dapagliflozin vs placebo to treat nonalcoholic fatty liver disease complicated with type 2 diabetes.
METHODS
PubMed, EMbase, Web of science, EBSCO and Cochrane library databases have been searched through July 2024, and we included randomized controlled trials (RCTs) assessing the efficacy of dapagliflozin for nonalcoholic fatty liver disease complicated with type 2 diabetes.
RESULTS
Five RCTs and 353 patients were included in the meta-analysis. Overall, compared with control intervention in patients with nonalcoholic fatty liver disease and type 2 diabetes, dapagliflozin treatment was able to significantly decrease ALT (standard mean difference [SMD] = -1.10; 95% confidence interval [CI] = -1.37 to -0.84; P < .00001), AST (MD = -1.32; 95% CI = -1.76 to -0.88; P < .00001) and HbA1c (SMD = -0.60; 95% CI = -1.02 to -0.17; P = .006), but demonstrated no influence on fasting glucose (SMD = -0.55; 95% CI = -1.10 to 0; P = .05), LDL-C (SMD = -0.19; 95% CI = -0.56 to 0.17; P = .30) or triglyceride (SMD = -0.30; 95% CI = -1.47 to 0.88; P = .62).
CONCLUSIONS
Dapagliflozin may benefit to treat patients with nonalcoholic fatty liver disease and type 2 diabetes.
引言
达格列净在治疗非酒精性脂肪性肝病合并2型糖尿病方面显示出一定潜力，本荟萃分析旨在探讨达格列净与安慰剂治疗非酒精性脂肪性肝病合并2型糖尿病的疗效。
方法
检索了截至2024年7月的PubMed、EMbase、Web of science、EBSCO和Cochrane图书馆数据库，纳入评估达格列净治疗非酒精性脂肪性肝病合并2型糖尿病疗效的随机对照试验（RCT）。
结果
荟萃分析纳入了5项RCT和353例患者。总体而言，与非酒精性脂肪性肝病和2型糖尿病患者的对照干预相比，达格列净治疗能够显著降低谷丙转氨酶（标准均差[SMD]=-1.10；95%置信区间[CI]=-1.37至-0.84；P<.00001）、谷草转氨酶（MD=-1.32；95%CI=-1.76至-0.88；P<.00001）和糖化血红蛋白（SMD=-0.60；95%CI=-1.02至-0.17；P=.006），但对空腹血糖（SMD=-0.55；95%CI=-1.10至0；P=.05）、低密度脂蛋白胆固醇（SMD=-0.19；95%CI=-0.56至0.17；P=.30）或甘油三酯（SMD=-0.30；95%CI=-1.47至0.88；P=.62）无影响。
结论
达格列净可能有益于治疗非酒精性脂肪性肝病合并2型糖尿病患者。
Zotero 插件